Search clinical trials for: Comparator: niacin ( ) laropiprant (MK0524A)

Total 55 results

Merck Sharp & Dohme LLC

Completed

Lipid Efficacy Study (0524B-022)(COMPLETED)

Primary Hypercholesterolemia | Mixed Hyperlipidemia
Merck Sharp & Dohme LLC

Completed

MK0524B Bioequivalence Study (0524B-070)

Dyslipidemia
Merck Sharp & Dohme LLC

Terminated

Carotid IMT (Intima Media Thickening) Study (0524A-041)(TERMINATED) (ACHIEVE)

Hypercholesterolemia, Familial
Merck Sharp & Dohme LLC

Completed

Effect of MK0524A on Cholesterol Levels (0524A-048)

Hypercholesterolemia | Hyperlipidemia
Merck Sharp & Dohme LLC

Completed

Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)

Diabetes Mellitus Type 2
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)

Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)

Dyslipidemia
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

MK0524A Phase IIb Study (0524A-011)(COMPLETED)

Flushing
Merck Sharp & Dohme LLC

Completed

MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED)

Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)

Hypercholesterolemia | Hyperlipidemia
Merck Sharp & Dohme LLC

Completed

Lipid Efficacy/Tolerability Study (0524A-020)

Primary Hypercholesterolaemia | Mixed Hyperlipidaemia
Merck Sharp & Dohme LLC

Completed

MK0524A Bioequivalence Study (0524A-059)

Dyslipidemia
Merck Sharp & Dohme LLC

Withdrawn

Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)

Dyslipidemia
Merck Sharp & Dohme LLC

Completed

Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)

Mixed Dyslipidemia | Primary Hypercholesterolemia
Merck Sharp & Dohme LLC

Terminated

Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)

Hypercholesterolemia | Mixed Dyslipidemia
Merck Sharp & Dohme LLC

Terminated

The Efficacy and Safety of MK0724 IV for Improvement of Neurological Damage and Recovery From Middle Cerebral Artery Ischemic Stroke (0724-018)

Middle Cerebral Artery Stroke
Merck Sharp & Dohme LLC

Terminated

A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)

Hypercholesterolemia, Familial | Heterozygous Familial Hypercholesterolemia
Vyne Therapeutics Inc.

Terminated

A Study of MK0594 in Patients With Alcohol Dependence (0594-020)

Alcohol Dependence
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)

Mixed Dyslipidemia | Primary Hypercholesterolemia
Merck Sharp & Dohme LLC

Terminated

A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)

Dyslipidemia | Primary Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)

Paranoid Schizophrenia
Merck Sharp & Dohme LLC

Completed

Effect of MK0524A on Flushing Caused by Niacin (0524A-056)

Flushing
Merck Sharp & Dohme LLC

Completed

MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)

Alzheimer's Disease
Organon and Co

Completed

To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)

Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)

Primary Hypercholesterolemia | Mixed Hyperlipidemia
Calmy Alexandra
University Hospital, Geneva; Swiss National Science Foundation; Swiss Heart Foundation and other collaborators

Terminated

ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART (NILACH)

Atherosclerosis | HIV

Switzerland
Instituto Aragones de Ciencias de la Salud
Hospital Miguel Servet

Completed

Effect of Niacin in the Lipoprotein (a) Concentration

Hypercholesterolemia

Spain
Rambam Health Care Campus

Unknown

The Effect of Niacin Administration on Oxidative Stress in Patients With Hypercholesterolmia, as Measured by the Use of a Novel Biomarker

Hypercholesterolemia

Israel
Merck Sharp & Dohme LLC

Completed

A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102)

Dyslipidemia
University Medical Centre Ljubljana

Completed

Niacin/Laropiprant and Endothelial Function

Coronary Heart Disease

Slovenia
Daniel A. Siniawski
Merck Sharp & Dohme LLC

Terminated

Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease

Coronary Artery Disease | Dyslipidemias

Argentina
Institut Investigacio Sanitaria Pere Virgili
Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders

Completed

Characterization of High Density Lipoprotein (HDL) in Type 2 Diabetes (T2D) After Fenofibrate or Niacin Treatment (LOWHDL)

Type 2 Diabetes Mellitus | Dyslipidemia

Spain
Merck Sharp & Dohme LLC

Completed

MK0524 Asthma POC Study (0524-008)(COMPLETED)

Asthma
Ludwig-Maximilians - University of Munich

Terminated

Effect of Niacin/Laropiprant on Postprandial Lipoprotein Metabolism in Patients With Dyslipoproteinemia

Metabolic Syndrome | Hyperlipoproteinemia

Germany
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)

Mixed Dyslipidemia | Primary Hypercholesterolemia
Bayside Health
National Health and Medical Research Council, Australia

Terminated

Effects of Niacin on Good Cholesterol in People With Peripheral Arterial Disease

Peripheral Arterial Disease

Australia
Sheba Medical Center

Terminated

The Impact of Tredaptive on Flow-Mediated Dilation in Cardiac Patients

Coronary Artery Disease | Dyslipidemia

Israel
Manchester University NHS Foundation Trust

Completed

Effect of Tredaptive on Serum Lipoproteins and Inflammatory Markers

Hypercholesterolemia

United Kingdom
Merck Sharp & Dohme LLC

Completed

Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)

Hyperlipidemia | Hypercholesteremia
George Thanassoulis
Jewish General Hospital; Laval University; Quebec Heart Institute

Withdrawn

Early Aortic Valve Lipoprotein(a) Lowering Trial (EAVaLL)

Aortic Stenosis and Lipoprotein(a) Levels

Canada
Hull University Teaching Hospitals NHS Trust
Merck Sharp & Dohme LLC

Completed

Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome

Polycystic Ovary Syndrome

United Kingdom
University of Oxford
Merck Sharp & Dohme LLC

Completed

Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE (HPS2-THRIVE)

Cardiovascular Disease | Diabetes Mellitus | Peripheral Arterial Disease | Coronary Heart Disease

United Kingdom
Merck Sharp & Dohme LLC

Terminated

Treatment of Refractory Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea/Hypopnea Syndrome (OSA/HS) Using Nasal Continuous Positive Airway Pressure (nCPAP) Therapy (0249-015)

Sleep Apnea, Obstructive | Hypopnea Syndrome | Excessive Daytime Sleepiness
University of Ioannina

Unknown

Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia

Dyslipidemia

Greece
Merck Sharp & Dohme LLC

Completed

A Study of Niaspan on Endothelium-Dependent and Endothelium-Independent Vascular Reactivity (0000-093)

Dyslipidemia
University of California, Irvine

Completed

Nicotinamide as an Early Alzheimer's Disease Treatment (NEAT)

Mild Cognitive Impairment | Alzheimer's Disease

United States
Merck Sharp & Dohme LLC

Completed

Effects of Niaspan™ on High-density Lipoprotein (HDL) in Healthy Male Subjects (0000-069)

Dyslipidemia
Johns Hopkins University
National Institute on Drug Abuse (NIDA); University of Alabama at Birmingham; New York University

Recruiting

5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder

Tobacco Use Disorder

United States
Merck Sharp & Dohme LLC

Completed

Endpoint Validation Study (0524A-015)

Flushing

3

Subscribe